Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGFβR Regulating TGF-β/Smad Pathway

Figure 3

Transcriptome sequencing assay in HepG2 cells with BBR treatment. HepG2 cells were treated with berberine. Furthermore, the transcriptome sequencing technology was performed by Shanghai Yasunari biotechnology company (a). The pathway analysis showed a significant difference in the TGF-β signaling pathway in 12 h and 24 h (b) and (c). The genes were reported closely related to EMT and have significant differences in transcription level (Tables 1 and 2). The top 20 with a lower value was shown.

(a)

(b)

(c)